{"id":450566,"date":"2021-03-04T08:03:35","date_gmt":"2021-03-04T13:03:35","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=450566"},"modified":"2021-03-04T08:03:35","modified_gmt":"2021-03-04T13:03:35","slug":"replimune-to-present-at-three-upcoming-investor-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/replimune-to-present-at-three-upcoming-investor-conferences\/","title":{"rendered":"Replimune to Present at Three Upcoming Investor Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">WOBURN, Mass., March  04, 2021  (GLOBE NEWSWIRE) &#8212; Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic\u2122 platform, today announced that members from the Replimune management team will present and host one-on-one meetings at the following three virtual investor conferences.<\/p>\n<p>H.C. Wainwright Global Life Sciences Conference <br \/>Date: March 9-10, 2021<br \/>Pre-Recorded Formal Presentation will be made live: Tuesday, March 9, 2021 at 7:00 am ET<\/p>\n<p>Barclays Global Healthcare Conference<br \/>Date: Thursday, March 11, 2021<br \/>Fireside Chat Presentation Time: 9:10 am ET<\/p>\n<p>33rd Annual Roth Conference<br \/>Date: Wednesday, March 17, 2021<br \/>Presentation Time: 1:30 pm ET<\/p>\n<p>A simultaneous webcast of the fireside chat presentation at the Barclays Global Healthcare Conference will be available in the Investors section of Replimune\u2019s website at www.replimune.com. A replay will be available for approximately 90 days following the conference.<\/p>\n<p>\n        <strong>About Replimune <\/strong><br \/>\n        <br \/>Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 to develop the next generation of oncolytic immune-gene therapies for the treatment of cancer. Replimune is developing novel, proprietary therapeutics intended to improve the direct cancer-killing effects of selective virus replication and the potency of the immune response to the tumor antigens released. Replimune\u2019s Immulytic\u2122 platform is designed to maximize systemic immune activation, in particular to tumor neoantigens, through robust viral-mediated immunogenic tumor cell killing and the delivery of optimal combinations of immune-activating proteins to the tumor and draining lymph nodes. The approach is expected to be highly synergistic with immune checkpoint blockade and other approaches to cancer treatment across a broad range of cancers. Replimune intends to progress these therapies rapidly through clinical development in combination with other immuno-oncology products with complementary mechanisms of action as well as in standalone indications.\u00a0For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=x2jgVdwYSQTlT2MeCj-aFjO0BQMGwUD1FIv0SCuYBRaJkrRB7nuWZBpTwdsVbIsyhET9LrtzKdfb-8UinLEcaA==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.replimune.com<\/a>.<\/p>\n<p>\n        <strong>Investor Inquiries <\/strong><br \/>\n        <br \/>Chris Brinzey<br \/>Westwicke, an ICR Company<br \/>339.970.2843<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=L6F6oQePbPuPzU5eiVGOpbBjdw4MnFbNEgDfakVGOSWBKitO4yqaU7d5CQE7xgS620mh-UI013UEwgerZ9vEnso-oMvtUOevEOKXE54JsTIqitDChLIBbF1nv15W_XNe\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">chris.brinzey@westwicke.com<\/a><\/p>\n<p>\n        <strong>Media Inquiries<\/strong><br \/>\n        <br \/>Arleen Goldenberg <br \/>Verge Scientific Communications<br \/>917.548.1582<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Eg5rOzQ0vpfEVDEJKa1qEkahsGj5QKWq0O5xmXTubonodKcCYp8oWhpJcrvZ7HnR0tviiC95jH-uvDpnAB3alB7JJ1UiVejV_puSaYtDB_hJ467xyZ5HQHm37hx1enRc\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">agoldenberg@vergescientific.com<\/a><\/p>\n<p \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NDIwMSM0MDQ3OTI5IzIxMTA1MzA=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/b01284e0-6bdf-41df-ac31-2b42697f0c55\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>WOBURN, Mass., March 04, 2021 (GLOBE NEWSWIRE) &#8212; Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic\u2122 platform, today announced that members from the Replimune management team will present and host one-on-one meetings at the following three virtual investor conferences. H.C. Wainwright Global Life Sciences Conference Date: March 9-10, 2021Pre-Recorded Formal Presentation will be made live: Tuesday, March 9, 2021 at 7:00 am ET Barclays Global Healthcare ConferenceDate: Thursday, March 11, 2021Fireside Chat Presentation Time: 9:10 am ET 33rd Annual Roth ConferenceDate: Wednesday, March 17, 2021Presentation Time: 1:30 pm ET A simultaneous webcast of the fireside chat presentation at the Barclays Global Healthcare Conference will be available in the Investors section of Replimune\u2019s &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/replimune-to-present-at-three-upcoming-investor-conferences\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Replimune to Present at Three Upcoming Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-450566","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Replimune to Present at Three Upcoming Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/replimune-to-present-at-three-upcoming-investor-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Replimune to Present at Three Upcoming Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"WOBURN, Mass., March 04, 2021 (GLOBE NEWSWIRE) &#8212; Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic\u2122 platform, today announced that members from the Replimune management team will present and host one-on-one meetings at the following three virtual investor conferences. H.C. Wainwright Global Life Sciences Conference Date: March 9-10, 2021Pre-Recorded Formal Presentation will be made live: Tuesday, March 9, 2021 at 7:00 am ET Barclays Global Healthcare ConferenceDate: Thursday, March 11, 2021Fireside Chat Presentation Time: 9:10 am ET 33rd Annual Roth ConferenceDate: Wednesday, March 17, 2021Presentation Time: 1:30 pm ET A simultaneous webcast of the fireside chat presentation at the Barclays Global Healthcare Conference will be available in the Investors section of Replimune\u2019s &hellip; Continue reading &quot;Replimune to Present at Three Upcoming Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/replimune-to-present-at-three-upcoming-investor-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-04T13:03:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NDIwMSM0MDQ3OTI5IzIxMTA1MzA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/replimune-to-present-at-three-upcoming-investor-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/replimune-to-present-at-three-upcoming-investor-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Replimune to Present at Three Upcoming Investor Conferences\",\"datePublished\":\"2021-03-04T13:03:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/replimune-to-present-at-three-upcoming-investor-conferences\\\/\"},\"wordCount\":311,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/replimune-to-present-at-three-upcoming-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NDIwMSM0MDQ3OTI5IzIxMTA1MzA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/replimune-to-present-at-three-upcoming-investor-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/replimune-to-present-at-three-upcoming-investor-conferences\\\/\",\"name\":\"Replimune to Present at Three Upcoming Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/replimune-to-present-at-three-upcoming-investor-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/replimune-to-present-at-three-upcoming-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NDIwMSM0MDQ3OTI5IzIxMTA1MzA=\",\"datePublished\":\"2021-03-04T13:03:35+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/replimune-to-present-at-three-upcoming-investor-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/replimune-to-present-at-three-upcoming-investor-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/replimune-to-present-at-three-upcoming-investor-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NDIwMSM0MDQ3OTI5IzIxMTA1MzA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NDIwMSM0MDQ3OTI5IzIxMTA1MzA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/replimune-to-present-at-three-upcoming-investor-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Replimune to Present at Three Upcoming Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Replimune to Present at Three Upcoming Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/replimune-to-present-at-three-upcoming-investor-conferences\/","og_locale":"en_US","og_type":"article","og_title":"Replimune to Present at Three Upcoming Investor Conferences - Market Newsdesk","og_description":"WOBURN, Mass., March 04, 2021 (GLOBE NEWSWIRE) &#8212; Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic\u2122 platform, today announced that members from the Replimune management team will present and host one-on-one meetings at the following three virtual investor conferences. H.C. Wainwright Global Life Sciences Conference Date: March 9-10, 2021Pre-Recorded Formal Presentation will be made live: Tuesday, March 9, 2021 at 7:00 am ET Barclays Global Healthcare ConferenceDate: Thursday, March 11, 2021Fireside Chat Presentation Time: 9:10 am ET 33rd Annual Roth ConferenceDate: Wednesday, March 17, 2021Presentation Time: 1:30 pm ET A simultaneous webcast of the fireside chat presentation at the Barclays Global Healthcare Conference will be available in the Investors section of Replimune\u2019s &hellip; Continue reading \"Replimune to Present at Three Upcoming Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/replimune-to-present-at-three-upcoming-investor-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-04T13:03:35+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NDIwMSM0MDQ3OTI5IzIxMTA1MzA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/replimune-to-present-at-three-upcoming-investor-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/replimune-to-present-at-three-upcoming-investor-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Replimune to Present at Three Upcoming Investor Conferences","datePublished":"2021-03-04T13:03:35+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/replimune-to-present-at-three-upcoming-investor-conferences\/"},"wordCount":311,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/replimune-to-present-at-three-upcoming-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NDIwMSM0MDQ3OTI5IzIxMTA1MzA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/replimune-to-present-at-three-upcoming-investor-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/replimune-to-present-at-three-upcoming-investor-conferences\/","name":"Replimune to Present at Three Upcoming Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/replimune-to-present-at-three-upcoming-investor-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/replimune-to-present-at-three-upcoming-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NDIwMSM0MDQ3OTI5IzIxMTA1MzA=","datePublished":"2021-03-04T13:03:35+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/replimune-to-present-at-three-upcoming-investor-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/replimune-to-present-at-three-upcoming-investor-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/replimune-to-present-at-three-upcoming-investor-conferences\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NDIwMSM0MDQ3OTI5IzIxMTA1MzA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NDIwMSM0MDQ3OTI5IzIxMTA1MzA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/replimune-to-present-at-three-upcoming-investor-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Replimune to Present at Three Upcoming Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/450566","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=450566"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/450566\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=450566"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=450566"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=450566"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}